One widely used long acting treatment combines cabotegravir and rilpivirine. Cabotegravir belongs to a group of medicines called integrase strand transfer inhibitors, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor. Together, they interfere with HIV replication through different mechanisms.
Before starting injectable treatment, individuals generally need to achieve and maintain viral suppression using an appropriate antiretroviral regimen. Healthcare professionals also evaluate previous treatment experiences, possible drug resistance, medication interactions, and other medical considerations.
Injectable HIV medications release active ingredients into the body over an extended period. These medicines help maintain therapeutic drug concentrations between scheduled appointments.
Cabotegravir prevents HIV from integrating its genetic material into human immune cells. Rilpivirine interferes with reverse transcriptase, an enzyme required for HIV replication. Combining these medicines helps control viral activity through two different mechanisms.
Depending on the treatment and individual circumstances, healthcare professionals may recommend an oral lead in period before beginning injections. Some treatment options also allow injections to begin without an oral lead in.
Several injectable approaches are available for HIV prevention and treatment, although their purposes differ.
Cabotegravir: Used as a long acting injectable medicine for HIV prevention in eligible individuals.
Cabotegravir and rilpivirine: A combination treatment used for maintaining HIV viral suppression in eligible adults and certain adolescents.
Long acting treatment schedules: Depending on the approved medication and treatment plan, injections may be administered monthly or every two months.
It is important to understand that injectable HIV prevention medicines and injectable HIV treatment medicines serve different purposes. Prevention injections are intended for people who do not have HIV, while treatment injections are used by eligible individuals living with HIV.
Injectable HIV medications provide several potential benefits for individuals who meet treatment requirements. One significant advantage is the reduced need to take HIV medication every day. Instead of remembering daily tablets, individuals attend scheduled healthcare appointments for their injections.
This approach may support treatment consistency for people who experience difficulties with daily medication routines. It can also provide greater flexibility in everyday activities, depending on appointment schedules and individual circumstances.
However, injectable treatment is not suitable for everyone. Regular appointments and adherence to injection schedules remain essential for maintaining effective treatment.
Long acting injectable treatments offer several practical and medical advantages.
Reduced daily medication burden: Eligible individuals may not need to take daily oral HIV treatment.
Convenient dosing schedules: Some treatments require administration only once a month or once every two months.
Consistent medication exposure: Long acting formulations maintain medication levels over extended periods.
Treatment routine flexibility: Individuals may find scheduled injections easier to manage than daily tablets.
Ongoing viral suppression: When used correctly in eligible individuals, combination injectable treatment can maintain HIV viral suppression.
Alternative treatment approach: Injectable medications provide another option for people who prefer not to take daily oral medication.
The benefits vary according to individual health conditions, treatment history, and the ability to attend scheduled appointments.
Like other antiretroviral medicines, injectable HIV treatments can cause side effects. Injection site reactions are among the commonly reported effects. These may include temporary pain, swelling, redness, or discomfort around the injection area.
Other possible side effects include headache, fever, tiredness, nausea, and muscle pain. Most injection site reactions are temporary, although their severity and duration can vary.
Important considerations include:
Missed appointments: Delayed injections can reduce medication protection and may increase the risk of HIV developing resistance.
Drug interactions: Certain medicines and supplements can affect how injectable HIV medications work.
Treatment eligibility: Previous treatment failure and known drug resistance may influence suitability.
Medical monitoring: Healthcare professionals monitor viral load and overall treatment response.
Long acting medication effects: Because these medicines remain in the body for an extended period, side effects and drug interactions may continue after the last injection.
Individuals should discuss unexpected symptoms, missed doses, or treatment concerns with their healthcare professional. Regular monitoring and following the prescribed injection schedule are important parts of long acting HIV treatment.